haNK for infusion

BIOLOGICAL6 trials

Sponsors

ImmunityBio, Inc.

Conditions

Hepatocellular Carcinoma Non-resectableHepatocellular Carcinoma RecurrentPancreatic CancerSquamous Cell CarcinomaTriple Negative Breast Cancer

Phase 1

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

TerminatedNCT03329248

ImmunityBio, Inc.Pancreatic Cancer

Start: 2017-11-06End: 2019-11-01Updated: 2024-12-12

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

TerminatedNCT03387085

ImmunityBio, Inc.Triple Negative Breast Cancer

Start: 2018-03-19End: 2024-01-16Updated: 2024-08-09

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

TerminatedNCT03387111

ImmunityBio, Inc.Squamous Cell Carcinoma

Start: 2018-01-09End: 2021-01-11Updated: 2024-08-05

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

TerminatedNCT03387098

ImmunityBio, Inc.Pancreatic Cancer

Start: 2017-12-28End: 2019-01-15Updated: 2024-05-22

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

WithdrawnNCT03563170

ImmunityBio, Inc.Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent

Start: 2018-05-25End: 2019-08-23Updated: 2021-03-18

QUILT-3.080: NANT Pancreatic Cancer Vaccine

TerminatedNCT03586869

ImmunityBio, Inc.Pancreatic Cancer

Start: 2018-07-17End: 2019-08-01Updated: 2024-08-27

Related Papers

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater TNBC.

Journal of Clinical Oncology2019-05-204 citations

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.

Journal of Clinical Oncology2019-05-202 citations

Correlation between circulating cell-free RNA biomarkers and response during combination immunotherapy in previously refractory metastatic TNBC patients.

Journal of Clinical Oncology2019-05-201 citations

NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.

Journal of Clinical Oncology2019-01-298 citations